84 research outputs found
Relationship between food sensitization and serum leptin levels with local airway inflammation in allergic rhinitis
No full textCongress of the European-Academy-of-Allergy-and-Clinical-Immunology -- JUN 06-10, 2015 -- Barcelona, SPAINKISA, Ucler/0000-0002-8131-6810; Kalpaklioglu, A. Fusun/0000-0002-6548-6932…European Acad Allergy & Clin Immuno
Efficacy and safety of once daily triamcinolone acetonide aqueous nasal spray in adults with non-allergic and allergic rhinitis
No full textBackground: The efficacy of corticosteroid has not been thoroughly studied in the treatment of non-allergic rhinitis. This study was designed to compare the efficacy of nasal corticosteroid in patients with allergic rhinitis (AR), and non-allergic rhinitis (NAR). Methods: The efficacy of triamcinolone acetonide nasal spray (TANS) on total nasal symptom scores (TNSS), and nasal peak inspiratory flow rate (nPIFR) was studied in a six-week parallel-group trial of NAR (n: 25), and AR (n: 16) patients. Health-related quality of life (HRQoL) and Epworth Sleepiness Scale (ESS) were also analysed. Results: The TNSSs, and symptom scores of conjunctivitis, snoring, and postnasal drainage were significantly improved in both groups, after two and six weeks of treatment. In contrast to AR, patients with NAR had statistically significant improvement in nasal obstruction, and postnasal drainage beginning from two weeks of the treatment. nPIFR slightly increased in both groups. Scores of generic (SF-36), rhinitis specific (MiniRQLQ) and ESS questionnaires generally improved better in AR than MAR. TANS was well-tolerated in AR and NAR groups with minor adverse events including headache, nasal burning, and bitter mouth taste. Conclusions: Our study disproved the idea of ineffectiveness of corticosteroid treatment in NAR, and showed that triamcinolone acetate may be an alternative drug in the treatment of NAR. (C) 2012 SEICAP Published by Elsevier Espana, S.L. All rights reserved.Kirikkale University Projects of Scientific ResearchesKirikkale University [2007/4]This work was supported by a grant from Kirikkale University Projects of Scientific Researches (grant no: 2007/4) which was received by Baccioglu Kavut, and Kalpaklioglu
Association Between Tuberculosis and Atopy: Role of the CD14-159C/T Polymorphism
No full textBackground: The development of allergic hypersensitivity depends on both genetic and environmental factors. Different amounts of microbial products could affect patients with atopy and different genotypes. Objective: We aimed to evaluate the role of varying degrees of exposure to infection by Mycobacterium tuberculosis (tuberculosis) in atopic patients and analyze the association with genetic factors. Methods: We performed CD14-159C/T genotyping in atopic patients (n=118) and healthy individuals (n=62) and recorded the following variables: rural lifestyle, exposure to persons with tuberculosis, bacille Calmette-Guerin (BCG) vaccination, tuberculin skin test (TST), skin prick test, and phenotypes of atopy. Blood samples were analyzed for soluble-CD14 (sCD14), interferon (IFN) gamma, total immunoglobulin (Ig) E, and eosinophil levels. A score was used to identify the likelihood of exposure to tuberculosis. Results: Almost all the study participants had had a BCG vaccination, and half had a positive TST result. No differences were observed between atopic patients with high/low tuberculosis scores and CD14 genotypes in terms of atopic phenotypes, allergen sensitization, and levels of total IgE, sCD14, and IFN-gamma. However, the frequency of asthma was higher in atopic patients with a high tuberculosis score and was not associated with CD14 genotypes. Eosinophil counts in blood were higher in atopic patients with a high tuberculosis score and CC+CT genotypes. Conclusions: These results suggest that the C allele of the CD14-159C/T polymorphism has a marked effect on eosinophil levels in atopic patients with increased exposure to tuberculosis. In addition, the degree of exposure to tuberculosis in atopic patients may modify the development of asthma.Kirikkale UniversityKirikkale University [2008/5]This work was supported by a grant from Kirikkale University Projects of Scientific Research (Grant No. 2008/5) awarded to Drs Baccioglu Kavut, Kalpaklioglu, and Ayaslioglu. None of the authors have any other financial disclosures to make
Current practice of allergy diagnosis and the potential impact of regulation in Europe
No full textDemoly, Pascal/0000-0001-7827-7964; Kalpaklioglu, A. Fusun/0000-0002-6548-6932; DR. FARID, S.H. M.H. M. Kn. - FR FARID/0000-0003-0372-4963; Hoffman, Hans Jurgen/0000-0002-6743-7931; Dreborg, Sten/0000-0002-3544-1557; Popov, Todor/0000-0001-5052-5866; Cardona, Victoria/0000-0003-2197-9767In the European Union (EU), the regulatory framework regarding diagnostic allergen extracts is currently in the process of being implemented at the national level. Due to these regulations, the initial and periodic renewal expenses for the registration of diagnostic allergen extracts may render extract production unprofitable. Consequently, many extracts may be at risk of removal from the market. The current survey, which was conducted by a task force of the European Academy of Allergy and Clinical Immunology, aimed to assess the current practice of allergy diagnosis in Europe. This survey revealed that skin tests continue to be the main diagnostic procedure and are used as the first option in almost two-third of all types of allergic diseases and in 90% of individuals suffering from respiratory allergies. Therefore, there is a need to ensure the availability of high-quality allergen extracts to maintain the common diagnostic procedures used by EU professionals. To reach this goal, it is necessary to align efforts and establish active partnerships between manufacturers, relevant scientific societies, consumer organizations and authorities to maintain the availability of these diagnostic tools
Efficacy and safety of H1-antihistamines: An update
No full textH1-antihistamines are inverse agonists that combine with and stabilize inactive conformation of H1-receptors. Thus they interfere with actions of histamine at H1-receptors. They are widely used for treatment of allergic rhinitis, allergic conjunctivitis, urticaria, coughs, colds and insomnia. H1-antihistamines are classified as older 'first generation' and newer 'second generation'. First generation H1-antihistamines have poor receptor H1-receptor selectivity, and cross blood-brain-barrier. They have a lot of adverse events such as anti-muscarinic, anti-?-adrenergic, anti-serotonin, and sedative effects. In contrast, second generation H1-antihistamines were highly selective for the histamine H1-receptor, do not cross the blood brain barrier, and have minimal adverse events. The risks of first-generation H1-antihistamines have been clearly underestimated, particularly when purchased as nonprescribed over the counter medications by public. This review summarizes curent literature to evaluate antihistamines including their mechanism, indications and side-effects. © 2012 Bentham Science Publishers
Is CRP a useful marker for inflammation in different forms of rhinitis?
No full text63rd Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology -- FEB 23-27, 2007 -- San Diego, CA…Amer Acad Allergy, Asthma & Immuno
Heterogeneity of pollen food allergy syndrome in seven Southern European countries: the @IT.2020 multicenter study
No full textSA was supported by the EAACI Fellowship Award of the European Academy of Allergology and Clinical Immunology. The study has been supported by an unrestricted grant from Euroimmun (grant number 118583).Lipp, T., Acar Şahin, A., Aggelidis, X., Arasi, S., Barbalace, A., Bourgoin, A., Bregu, B., Brighetti, M.A., Caeiro, E., Caglayan Sozmen, S., Caminiti, L., Charpin, D., Couto, M., Delgado, L., Di Rienzo Businco, A., Dimier, C., Dimou, M.V., Fonseca, J.A., Goksel, O., Guvensen, A., Hernandez, D., Hoffmann, T.M., Jang, D.T., Kalpaklioglu, F., Lame, B., Llusar, R., Makris, M.P., Mazon, A., Mesonjesi, E., Nieto, A., Öztürk, A., Pahus, L., Pajno, G.B., Panasiti, I., Papadopoulos, N.G., Pellegrini, E., Pelosi, S., Pereira, A.M., Pereira, M., Pinar, M., Potapova, E., Priftanji, A., Psarros, F., Sackesen, C., Sfika, I., Suarez, J., Thibaudon, M., Travaglini, A., Tripodi, S., Verdier, V., Villella, V., Xepapadaki, P., Yazici, D., Matricardi, P.M., Dramburg, S
A case of recurrent angioedema in a 12-year-old girl
No full textEuropean-Academy-of-Allergy-and-Clinical-Immunology Congress -- JUN 07-11, 2014 -- Copenhagen, DENMARKKalpaklioglu, A. Fusun/0000-0002-6548-6932…European Acad Allergy & Clin Immuno
Successful pregnancy outcome after treatment with C1-inhibitor concentrate in a patient with hereditary angioedema
No full textEuropean-Academy-of-Allergy-and-Clinical-Immunology Congress -- JUN 07-11, 2014 -- Copenhagen, DENMARKKalpaklioglu, A. Fusun/0000-0002-6548-6932…European Acad Allergy & Clin Immuno
Airway nitric oxide levels in drug provocation test: A new diagnostic tool?
No full textCongress of the European-Academy-of-Allergy-and-Clinical-Immunology -- JUN 17-21, 2017 -- Helsinki, FINLANDKalpaklioglu, A. Fusun/0000-0002-6548-6932…European Acad Allergy & Clin Immuno
- …
